Macquarie Group
INO icon

Macquarie Group’s Inovio Pharmaceuticals INO Stock Holding History

Macquarie Group’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-125
Closed -$1.01K – 1787
2024
Q2 		$1.01K Sell
125
-714
-85% -$7.51K ﹤0.01% 1839
2024
Q1 		$12 Buy
+839
New +$7.24K ﹤0.01% 1718
2022
Q4 		– Sell
-441
Closed -$14K – 1939
2022
Q3 		$14K Sell
441
-257
-37% -$6.58K ﹤0.01% 2296
2022
Q2 		$14K Hold
698
– – ﹤0.01% 2391
2022
Q1 		$30 Hold
698
– – ﹤0.01% 2297
2021
Q4 		$42K Hold
698
– – ﹤0.01% 2211
2021
Q3 		$60K Hold
698
– – ﹤0.01% 2171
2021
Q2 		$78K Hold
698
– – ﹤0.01% 2040
2021
Q1 		$78K Buy
698
+192
+38% +$25.3K ﹤0.01% 1968
2020
Q4 		$54K Hold
506
– – ﹤0.01% 2020
2020
Q3 		$70K Hold
506
– – ﹤0.01% 1870
2020
Q2 		$164K Buy
+506
New +$81.3K ﹤0.01% 1607

Other funds holding INO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Macquarie Group's INO Position: Q3 2024 in Review

Macquarie Group sold out of Inovio Pharmaceuticals (INO) in Q3 2024, closing a stake of 125 shares — an estimated $1.01K sold.

Macquarie Group first reported a position in INO in Q2 2020 and held it in 12 quarters. The position peaked at $164K in Q2 2020. 98 funds tracked by Wall St. Rank hold INO as of Q3 2024.

  • Macquarie Group reported no remaining Inovio Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Macquarie Group sold 125 Inovio Pharmaceuticals shares in Q3 2024, an estimated $1.01K.
  • Macquarie Group first reported a position in Inovio Pharmaceuticals in Q2 2020 and held it in 12 quarters.
  • Macquarie Group's Inovio Pharmaceuticals position peaked at $164K in Q2 2020.
  • 98 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q3 2024.

Based on Macquarie Group's 13F filing for Q3 2024, filed 14 Nov 2024.